Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Harmony Biosciences Holdings (HRMY) EBIAT (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed EBIAT for 7 consecutive years, with $22.5 million as the latest value for Q4 2025.

  • Quarterly EBIAT fell 54.55% to $22.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $158.7 million through Dec 2025, up 9.07% year-over-year, with the annual reading at $158.7 million for FY2025, 9.07% up from the prior year.
  • EBIAT hit $22.5 million in Q4 2025 for Harmony Biosciences Holdings, down from $50.9 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $87.9 million in Q3 2022 to a low of -$9.6 million in Q3 2021.
  • Historically, EBIAT has averaged $32.5 million across 5 years, with a median of $31.9 million in 2023.
  • Biggest YoY gain for EBIAT was 52385.19% in 2021; the steepest drop was 603.93% in 2021.
  • Year by year, EBIAT stood at $22.7 million in 2021, then surged by 113.56% to $48.5 million in 2022, then plummeted by 45.15% to $26.6 million in 2023, then surged by 85.95% to $49.5 million in 2024, then crashed by 54.55% to $22.5 million in 2025.
  • Business Quant data shows EBIAT for HRMY at $22.5 million in Q4 2025, $50.9 million in Q3 2025, and $39.8 million in Q2 2025.